J Thromb Haemost 2004;2: 1882 8. 56. Cuker A, Arepally G, Crowther MA, et al. The HIT expert probability (HEP) score: a novel pre-test probability model 660 Ann Thorac Surg ANTICOAGULATION DURING CARDIOPULMONARY BYPASS 2018;105:650 62 REPORT for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642 50. 57. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Pre- dictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012;120:4160 7. 58. Warkentin TE, Kelton JG. Temporal aspects of heparin- induced thrombocytopenia. N Engl J Med 2001;344:1286 92. 59. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703 8. 60. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin- dependent antibodies. Br J Haematol 2005;128:837 41. 61. Warkentin TE, Greinacher A. Heparin-induced thrombo- cytopenia: recognition, treatment, and prevention: the sev- enth ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):311 37. 62. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin- induced recurrent anaphylaxis. Clin Exp Allergy 2004;34: 1916 8. 63. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007;157:514 7. 64. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological pro le: an update. Blood Coagul Fibrinolysis 2006;17:605 13. 65. Koster A, Spiess B, Chew DP, et al. Effectiveness of biva- lirudin as a replacement for heparin during cardiopulmo- nary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93:356 9. 66. Zucker ML, Koster A, Prats J, Laduca FM. 